Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor

Victoria E Cheng1, Anne Oppermen1, Dinesh Natarajan1

  • 1Department of Cardiology, Western Hospital, Gordon Street, Footscray, Melbourne, Australia.

Heart, Lung & Circulation
|February 1, 2014
PubMed

Insights

A patient experienced an omental bleed after straining, despite no clear risk factors besides dual antiplatelet therapy. This case highlights a rare complication potentially linked to intra-abdominal pressure and antiplatelet use.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Vascular Surgery

Background:

  • A 68-year-old man with a history of ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery presented with recurrent chest pain.
  • Initial evaluation showed no acute ischemic changes on ECG, and symptoms resolved with nitrates.

Observation:

  • The patient later developed severe left-sided abdominal pain and hypovolemic shock after straining.
  • Abdominal computed tomography (CT) revealed an omental bleed, necessitating an emergency laparotomy.

Findings:

  • The omental bleed was presumed to be associated with dual antiplatelet therapy (aspirin and ticagrelor) and potentially elevated intra-abdominal pressure from straining.
  • No other significant risk factors for bleeding were identified.

Implications:

  • This case underscores the potential for spontaneous omental bleeds as a rare complication in patients on dual antiplatelet therapy, particularly when combined with increased intra-abdominal pressure.
  • Further investigation into the interplay between antiplatelet agents, intra-abdominal pressure, and gastrointestinal bleeding may be warranted.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K